China Pharma (CPHI) vs TherapeuticsMD (TXMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TherapeuticsMD (TXMD) has outperformed China Pharma (CPHI) over the past year, losing 3.9% versus a loss of 72.6%. Over five years, TXMD leads with a -94.1% price change compared with -99.8% for CPHI. TherapeuticsMD is the larger company by market cap ($19.8 million vs $18.9 million), about 1.0 times the size.
TherapeuticsMD converts more of its revenue into profit, with a net margin of -18.8% versus -76.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | TXMD |
|---|---|---|
| Share price | $0.4384 | $1.71 |
| Market cap | $18.86M | $19.79M |
| 1-day change | -13.00% | -5.52% |
| YTD return | -63.77% | +4.91% |
| 1-year return | -72.60% | -3.93% |
| 5-year return | -99.84% | -94.10% |
| P/E ratio (TTM) | — | 171.00 |
| Forward P/E | — | 4.89 |
| EPS (TTM) | $-0.42 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.14M | $3.02M |
| Revenue growth (YoY) | -8.49% | +71.61% |
| Net income (latest FY) | $-3.19M | $-569.00K |
| Gross margin | -3.18% | — |
| Operating margin | -78.16% | -145.27% |
| Net margin | -76.91% | -18.83% |
| 52-week high | $19.19 | $2.95 |
| 52-week low | $0.38 | $1.43 |
| Distance from 52-week high | -97.72% | -42.03% |
| Average volume | 1.60M | 24.50K |
| Shares outstanding | 43.02M | 11.57M |
| Employees | 215 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXMD has outperformed CPHI by 68.7 percentage points over the past year.
- TherapeuticsMD is more profitable, keeping -18.8 cents of every revenue dollar as net income versus -76.9 cents for China Pharma.
- TherapeuticsMD grew revenue faster in its latest fiscal year (+71.61% vs -8.49%).
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About TherapeuticsMD
TXMD stock →TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
CPHI vs TXMD FAQ
Which is bigger, China Pharma or TherapeuticsMD?
TherapeuticsMD (TXMD) is larger, with a market capitalization of $19.79M compared with $18.86M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or TXMD?
TXMD returned -3.93% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and TherapeuticsMD in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.